Finally, as mentioned in the pancreatic cancer section, MSLN expression may be non-invasively evaluated in ovarian cancer, using 89Zr-labeled anti-MSLN Ab (309), which may help patient selection for therapy. This evidence concerns the gene MSLN and pancreatic neoplasm.